Does Rallies show live market data for PLX?

Rallies combines live market context with ticker research for PLX, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.

PLX (Protalix BioTherapeutics, Inc. Common Stock) Stock Analysis

Protalix BioTherapeutics, Inc. Common Stock (PLX) is a publicly traded Healthcare sector company. As of May 21, 2026, PLX trades at $1.94 with a market cap of $153.89M and a P/E ratio of 10.07. PLX moved +5.53% today. Year to date, PLX is +12.29%; over the trailing twelve months it is +16.86%. Its 52-week range spans $0.99 to $3.19. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces PLX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the latest PLX stock research?

Protalix BioTherapeutics, Inc. Common Stock (PLX) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. PLX moved +5.53% today. Analyst consensus is buy.

PLX Key Metrics

Key financial metrics for PLX
Metric	Value
Price	$1.94
Market Cap	$153.89M
P/E Ratio	10.07
EPS	$0.20
Dividend Yield	0.00%
52-Week High	$3.19
52-Week Low	$0.99
Volume	678.76K
Avg Volume	0
Revenue (TTM)	$76.38M
Net Income	$15.33M
Gross Margin	69.97%

Latest PLX News

Protalix Extends Cash Runway into Late 2027, Completes Phase III Enrollment — May 14, 2026
Protalix Q1 Revenues Fall to $7.4M, Reaffirms $78–$83M 2026 Guidance After $25M Milestone — May 13, 2026
Protalix BioTherapeutics secures €25M after EU dosing approval, forecasts 50% growth — Mar 18, 2026
Protalix wins EU approval for monthly Elfabrio dosing, nets $25M — Mar 18, 2026
Protalix and Chiesi Secure EU Approval for 2mg/kg Every-Four-Weeks Dose, Triggering $25M Payment — Mar 9, 2026

Recent PLX Insider Trades

Bashan Dror bought 56.00K (~$101.36K) on Dec 19, 2025.
Bar-Shalev Amos sold 168 (~$314.16) on Nov 18, 2025.
Schwartz Aharon bought 129.00K (~$205.88K) on Jun 10, 2025.

PLX Analyst Consensus

1 analysts cover PLX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.

Common questions about PLX

What can I research for PLX on Rallies?: Protalix BioTherapeutics, Inc. Common Stock (PLX) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. PLX moved +5.53% today. Analyst consensus is buy.
Does Rallies show live market data for PLX?: Rallies combines live market context with ticker research for PLX, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.